New hope for liver cancer patients as experimental drug enters first human trials
NCT ID NCT07364357
Summary
This is a very early-stage study to test the safety of a new drug called CREPT-618 in adults with advanced liver cancer that has stopped responding to standard treatments. The main goal is to find a safe dose by giving small groups of patients increasing amounts of the drug and watching closely for side effects. Researchers will also check if the drug shows any early signs of helping to control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
RECRUITINGBeijing, 100021, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.